B 1344
Alternative Names: B-1344Latest Information Update: 28 Sep 2025
At a glance
- Originator Shanghai Institute of Nutrition and Health
- Developer Tasly Pharmaceutical Group
- Class Fibroblast growth factors; Hepatoprotectants
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic fatty liver disease
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Sep 2025 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in USA (SC, Injection)
- 24 Jul 2025 Phase-I for Non-alcoholic fatty liver disease in China (SC) (NCT07128797)
- 28 Jun 2024 No recent reports of development identified for preclinical development in Non-alcoholic-fatty-liver-disease in China (Parenteral)